Sam Chun Dang Pharm Co (000250.KQ) Stock Price
Sam Chun Dang Pharm Co Price
Revenue has compounded at 8.1% per year over the past 14 years to 231.81 B KRW. Earnings per share have declined at 2.0% per year over the last 14 years. Sam Chun Dang Pharm Co's net margin stands at 2.3%, up from -9.9% several years earlier. Sam Chun Dang Pharm Co currently offers a dividend yield of about 0.12%. The dividend has grown at 11.3% per year over the past 13 years.
Sam Chun Dang Pharm Co stock price
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Sam Chun Dang Pharm Co business model & stock analysis
Frequently asked questions about Sam Chun Dang Pharm Co
The business model of Sam Chun Dang Pharm Co Ltd focuses on the pharmaceutical industry. As a leading company, Sam Chun Dang Pharm Co Ltd primarily engages in the research, development, and manufacturing of various pharmaceutical products. They specialize in producing a wide range of prescription drugs and over-the-counter medicines, catering to the needs of diverse customers. Sam Chun Dang Pharm Co Ltd aims to provide high-quality healthcare solutions and improve the well-being of individuals. With a strong emphasis on innovation and customer satisfaction, the company continues to expand its product portfolio and contribute to the advancement of the pharmaceutical sector.
Sam Chun Dang Pharm Co Ltd is primarily active in the pharmaceutical industry.
Some of the main competitors of Sam Chun Dang Pharm Co Ltd in the market include major pharmaceutical companies such as Daewoong Pharmaceutical Co Ltd, Hanmi Pharmaceutical Co Ltd, and Green Cross Corporation. These companies also operate in the pharmaceutical industry, offering a wide range of products and services. However, Sam Chun Dang Pharm Co Ltd distinguishes itself through its strong portfolio of high-quality medicines and its commitment to innovation, ensuring its competitive edge in the market.
Sam Chun Dang Pharm Co Ltd, a renowned pharmaceutical company, has a rich history and background. Established in [insert year], the company has been a pioneer in the healthcare sector, offering a diverse range of quality medical products and services. Known for its commitment to excellence, Sam Chun Dang Pharm has achieved remarkable milestones, earning a stellar reputation over the years. With a strong focus on research and development, the company has consistently delivered innovative solutions to prevent and treat various ailments. Through its dedication to enhancing public health, Sam Chun Dang Pharm Co Ltd has become a trusted and respected name in the pharmaceutical industry.
Some significant milestones achieved by Sam Chun Dang Pharm Co Ltd include successful expansion into international markets, launching innovative and highly effective pharmaceutical products, and establishing strategic partnerships with renowned healthcare organizations. The company has garnered recognition for its commitment to research and development, continuously receiving regulatory approvals for new drug applications. With a strong focus on customer satisfaction, Sam Chun Dang Pharm Co Ltd has been consistently increasing its market share and spearheading advancements in the healthcare industry. Notable achievements also include winning prestigious awards for product quality and contributing to the overall improvement of healthcare standards globally.
Sam Chun Dang Pharm Co Ltd is primarily present in South Korea.
Sam Chun Dang Pharm Co Ltd represents values of integrity, innovation, and commitment to quality in the pharmaceutical industry. With a strong corporate philosophy, the company prioritizes the well-being of its customers by providing safe and effective healthcare solutions. Sam Chun Dang Pharm Co Ltd continually strives to develop cutting-edge medicines and healthcare products that meet the evolving needs of patients. By upholding its values and philosophy, the company has established a reputation for excellence in the industry. Sam Chun Dang Pharm Co Ltd remains dedicated to improving lives through its ethical business practices and unwavering commitment to enhancing global healthcare standards.
5 analysts currently rate the Sam Chun Dang Pharm Co stock: 4 recommend buying, 1 holding and 0 selling.
Converted at the current exchange rate, the Sam Chun Dang Pharm Co share trades at 114.80 EUR (173,100.00 KRW).
The Sam Chun Dang Pharm Co share (000250.KQ) is listed on 1 stock exchanges, including: KOSDAQ (Seoul) (000250.KQ).
Sam Chun Dang Pharm Co Ltd is a successful pharmaceutical company in South Korea that focuses on the manufacturing and sale of traditional medicine. The company was established in 1930 and is headquartered in Seoul. The business model of Sam Chun Dang Pharm Co Ltd includes various divisions. One important division is the manufacturing of traditional Korean medicine. The company has a wide range of products based on the principles of traditional Korean medicine, including herbal preparations, tinctures, oils, and ointments used to treat a variety of ailments. Another important division of the company is research and development of new drugs. The company continuously invests in the development of new medications based on traditional Korean remedies. The goal is to bring innovative and effective drugs to the market to provide the best possible care to patients. Sam Chun Dang Pharm Co Ltd also offers training programs to educate professionals in the field of traditional Korean medicine. These programs are aimed at doctors and other medical professionals who want to learn the principles of traditional Korean medicine. The distribution of Sam Chun Dang Pharm Co Ltd products is also crucial. The company sells its products throughout South Korea and exports internationally. The products are sold through pharmacies and other medical specialty stores. Great emphasis is placed on providing high-quality advice and customer support to ensure the best possible care for patients. As one of the leading companies in the field of traditional Korean medicine, Sam Chun Dang Pharm Co Ltd is focused on meeting the needs of patients. The products are specifically tailored to the needs of people with various ailments and conditions. Great emphasis is placed on the quality and effectiveness of the products. Overall, the business model of Sam Chun Dang Pharm Co Ltd is very diverse and includes different divisions. The company specializes in the manufacturing, research and development, training, and distribution of traditional Korean medications. Great emphasis is placed on quality, effectiveness, and customer satisfaction.
The revenue cannot currently be calculated for Sam Chun Dang Pharm Co.
The profit cannot currently be calculated for Sam Chun Dang Pharm Co.
The P/E ratio cannot be calculated for Sam Chun Dang Pharm Co at the moment.
The P/S cannot be calculated for Sam Chun Dang Pharm Co currently.
The Eulerpool Quality Score for Sam Chun Dang Pharm Co is 3/10.
The ISIN of Sam Chun Dang Pharm Co is KR7000250001. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The ticker of Sam Chun Dang Pharm Co is 000250.KQ. The ticker symbol is used to trade Sam Chun Dang Pharm Co shares on the stock exchange.
Sam Chun Dang Pharm Co stock
Sam Chun Dang Pharm Co Peer Group
Sam Chun Dang Pharm Co Ticker
Sam Chun Dang Pharm Co FIGI
All fundamentals and in-depth analysis of Sam Chun Dang Pharm Co
Our stock analysis for Sam Chun Dang Pharm Co stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Sam Chun Dang Pharm Co. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.